Intensity Therapeutics, Inc. Announces Pricing of Public Offering

SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its underwritten public offering of 6,675,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $2,002,500, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,001,250 shares of common stock at the public offering price less discounts and commissions, to cover over-allotments. The offering is expected to close on June 13, 2025, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes.
ThinkEquity is acting as sole book-running manager for the offering.
The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-280681), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2024 and declared effective on July 11, 2024. The offering will be made only by means of a written prospectus and related prospectus supplement. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intensity Therapeutics, Inc:Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of the investigational new drug, INT230-6, to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com
Forward-Looking Statements:Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the completion of the public offering on the anticipated terms or at all, the Company's intended use of proceeds from the offering, the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company may not satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; and other risks described in the section entitled "Risk Factors" in the Company's preliminary prospectus supplement filed with the SEC, the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
For Investor Relations Inquiries:
Investor Relations Contact:Justin KulikJustin@coreir.comCORE IR(516) 222-2560
Media Contact:Jules AbrahamCORE IRpr@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-announces-pricing-of-public-offering-302479812.html
SOURCE Intensity Therapeutics Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

23 minutes ago

• Yahoo

Chip equipment stocks fall after US plans to revoke China waivers

-- Taiwan Semiconductor Manufacturing (NYSE:TSM) stock fell 2%, Lam Research (NASDAQ:LRCX) shares tumbled 5%, and Applied Materials (NASDAQ:AMAT) dropped 4% following reports that a U.S. official plans to revoke technology waivers for chipmakers operating in China. Jeffrey Kessler, who leads the export controls unit at the Commerce Department, has informed major semiconductor manufacturers including Taiwan Semiconductor Manufacturing, Samsung Electronics (KS:005930), and SK Hynix of his intention to cancel blanket waivers that currently allow them to ship American chip-making equipment to their factories in China without applying for separate licenses each time, according to the Wall Street Journal. The potential policy change is reportedly part of the Trump administration's broader efforts to restrict critical U.S. technology from going to China. If implemented, the move could create significant disruption both diplomatically and economically, coming shortly after the U.S. and China established a trade truce in London. White House officials have stated that this action would not represent a new trade escalation but would instead align the licensing system for chip equipment with China's existing system for rare-earth materials. They added that the U.S. and China continue to make progress on completing their London agreement. "Chip makers will still be able to operate in China. The new enforcement mechanisms on chips mirror licensing requirements that apply to other semiconductor companies that export to China and ensure the United States has an equal and reciprocal process," a Commerce Department spokesman said. The semiconductor equipment sector is particularly vulnerable to changes in U.S.-China trade policy, as many companies rely on access to the Chinese market for significant portions of their revenue. Related articles Chip equipment stocks fall after US plans to revoke China waivers QXO won't participate in bidding war for GMS - source Reddit in talks to use Sam Altman's World ID for user verification - Semafor

Yahoo

26 minutes ago

• Yahoo

Netflix's 40% Rally Spurs Top Target Hike

Netflix (NASDAQ:NFLX) has been on a tear this year, up roughly 40% thanks to a killer Q1, healthy subscriber adds and the growing appeal of its cheaper, ad-supported tier. Pivotal's four-star analyst Jeff Wlodarczak clearly likes what he sees: he bumped his price objective from $1,350 to $1,600, which still leaves about 24% upside if Netflix hits that mark. What's his logic? First, Netflix's brand and massive library remain unrivaledthink of them as the crown jewels that keep folks hooked. Second, there's plenty of room left abroad. Even though Netflix is already in nearly every country, emerging markets haven't been fully tapped yet. Wlodarczak expects big subscriber gains there over the long haul. He also pointed out how the ad-tier adds a value play: it brings in price-sensitive viewers and lifts average revenue per user without breaking the bank. And yes, there's that eyebrow-raising $1 trillion market-cap goal for 2030. It sounds ambitious, but Pivotal argues that consistent execution and global expansion could get Netflix there. This article first appeared on GuruFocus. Sign in to access your portfolio

Yahoo

37 minutes ago

• Yahoo

2 Glorious Growth Stocks Down 36% and 57% You'll Wish You'd Bought on the Dip, According to Wall Street

The S&P 500 is hovering near an all-time high, but some stocks in the software space still haven't reclaimed their best levels from 2021. Datadog and Workiva are two of those stocks, but their strong businesses could fuel a recovery over the long term. Analysts have reached a very bullish consensus on both Datadog and Workiva. 10 stocks we like better than Datadog › The S&P 500 (SNPINDEX: ^GSPC) has almost fully recovered from its recent 19% drop, which was triggered by President Donald Trump's "Liberation Day" tariffs in April. But not every stock is following along -- in fact, many enterprise software stocks still haven't reclaimed their record highs from 2021. Datadog (NASDAQ: DDOG) and Workiva (NYSE: WK) are two of those stocks. They were incredibly overvalued when they peaked a few years ago, and they are still down by 36% and 57%, respectively, from those lofty levels. But they're starting to look quite attractive. The majority of the analysts tracked by The Wall Street Journal who cover Datadog stock and Workiva stock have assigned them the highest possible buy rating. Here's why their optimism might be justified. Datadog developed an observability platform that monitors cloud infrastructure around the clock, alerting businesses to technical issues and outages which they might not have discovered until customers were affected or sales were lost (at which point it's too late). Over 30,500 businesses are using Datadog, and they operate in many different industries, including gaming, manufacturing, financial services, retail, and more. Last year, Datadog expanded into artificial intelligence (AI) observability with a new tool that helps developers troubleshoot technical issues, track costs, and assess the outputs of their large language models (LLMs). During the recent first quarter of 2025 (ended March 31), the company said that the number of customers using this new tool more than doubled compared to just six months earlier, which suggests it's gaining serious traction. Datadog also offers other AI products, like a monitoring solution for businesses using ready-made LLMs from OpenAI, and an AI-powered virtual assistant for its flagship observability platform. Overall, the company said that 4,000 customers were using at least one of its AI products in Q1, which also doubled year over year. On the back of a strong first-quarter result, Datadog raised the high end of its full-year revenue forecast for 2025 to $3.235 billion, up $40 million from management's original guidance. It would represent growth of 21% from the company's 2024 result, but it would still be a drop in the bucket compared to the $53 billion addressable opportunity in the observability space alone. Datadog was trading at a price-to-sales (P/S) ratio of around 70 when it peaked in 2021. But the 36% decline in the stock since then, in combination with the company's revenue growth, has pushed its P/S ratio down to 15.5. It's still elevated compared to many other enterprise software stocks, but it's much closer to the cheapest level since Datadog went public than it is to its lofty 2021 peak. The Wall Street Journal tracks 46 analysts who cover Datadog stock, and 31 have assigned it the highest possible buy rating. Seven others are in the overweight (bullish) camp, and the remaining eight recommend holding. No analysts recommend selling. Their average price target of $140.72 implies a potential upside of 15% over the next 12 to 18 months, but investors who hold the stock for the long term could do far better as Datadog's AI products gather momentum. Modern businesses often use dozens, or even hundreds, of digital applications to run their day-to-day operations. This is a nightmare for managers who are tasked with tracking workflows across all that software, but Workiva built an elegant solution to ease the burden. Workiva's platform integrates with most storage applications, systems of record, and productivity software, allowing managers to pull data from all of them onto one dashboard. This saves them from having to open hundreds of individual applications, and it also reduces human error, which is common when copying mountains of data manually. Once data is loaded into Workiva, managers can select from several different templates so they can rapidly compile regulatory filings or reports for senior executives. Workiva is also becoming a key player in the ESG (environmental, social, and governance) reporting space, offering a product that allows businesses to track their effect on all key stakeholders, not just those with a financial interest. With Workiva's ESG platform, organizations can create frameworks, track data, and compile reports on everything from their carbon emissions to the diversity of their workplace. Workiva had 6,385 total customers at the end of Q1 2025, which was a 5% increase from the year-ago period, but its highest-spending cohorts are growing significantly faster. For example, the number of customers with annual contract values of at least $100,000 grew by 23%, and those with annual contract values of at least $500,000 soared by 32%. In other words, larger organizations with more complex operations seem to be flocking to Workiva. The company expects to generate up to $868 million in total revenue in 2025, which would be a 17.5% increase compared to 2024. That would be a modest acceleration from the 17.3% growth it delivered last year. As is the case with Datadog, Workiva's P/S ratio is currently down significantly from its 2021 peak. It's at 4.8 as of this writing, which is near the cheapest level since the stock went public. The Wall Street Journal tracks 13 analysts who cover Workiva stock, and 11 of them have given it a buy rating. The remaining two are in the overweight camp, with none recommending to hold, let alone sell. Simply put, the analysts have reached a very bullish consensus. Their average price target of $97.64 implies an eye-popping potential upside of 44% over the next 12 to 18 months. But the stock could do even better over the long term, since Workiva has barely scratched the surface of its $35 billion addressable market. Before you buy stock in Datadog, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Datadog wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 992% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Datadog and Workiva. The Motley Fool has a disclosure policy. 2 Glorious Growth Stocks Down 36% and 57% You'll Wish You'd Bought on the Dip, According to Wall Street was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data